Lab Reagents
Human IgG antibody Laboratories manufactures the structure of spike rpotein reagents distributed by Genprice. The Structure Of Spike Rpotein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Structure products are available in stock. Specificity: Structure Category: Of Group: Spike Rpotein
Spike Rpotein information
Spike Glycoprotein Antibody (Biotin) |
20-abx300554 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN1) Spike Peptide |
3221P |
ProSci |
0.05 mg |
EUR 164.75 |
Description: (IN) SARS (IN1) Spike peptide |
SARS (IN2) Spike Peptide |
3223P |
ProSci |
0.05 mg |
EUR 164.75 |
Description: (IN) SARS (IN2) Spike peptide |
SARS (IN3) Spike Peptide |
3225P |
ProSci |
0.05 mg |
EUR 164.75 |
Description: (IN) SARS (IN3) Spike peptide |
Structure Specific Recognition Protein 1 Antibody |
20-abx115877 |
Abbexa |
|
|
|
Flap Structure-Specific Endonuclease 1 (Recombinant) |
20-abx073566 |
Abbexa |
-
EUR 4490.00
-
EUR 328.00
-
EUR 230.00
|
|
|
Coronavirus OC43 Spike glycoprotein Antibody |
20-abx109271 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
SARS-CoV spike protein Antibody |
abx023139-100ug |
Abbexa |
100 ug |
EUR 857 |
|
SARS-CoV spike protein Antibody |
abx023143-100ug |
Abbexa |
100 ug |
EUR 857 |
|